Hepatitis B virus infection in pregnant women and transmission to newborns

Khan Salman, Rashmi, Singh Priti, Madan Molly, Virmani Sunil Kumar, Siddiqui Zeenat

Research output: Contribution to journalReview article

2 Citations (Scopus)

Abstract

Chronic hepatitis B affects over 350 million people worldwide. India represents the second largest pool of chronic hepatitis B virus (HBV) infection in the world with an estimated 40 million infected people. Vertical transmission is known to be the leading cause of infection and perinatal infection is associated with a very high rate of chronicity (up to 90%). Hepatitis B e antigen (HBeAg) positivity indicates that replicative form of HBV may play a role in immunotolerance in utero by crossing the placenta. Up to 40% of chronically infected individuals will die prematurely from complications such as acute liver failure, cirrhosis and hepatocellular cancer. In case of HBeAg positivity and high viral load of mother, HBV immunoglobulin is preferably given along with HBV vaccination. Antiviral therapy is recommended for use in the third trimester of pregnancy to reduce the perinatal transmission of HBV, however, use of antiviral therapy should be individualized during pregnancy. Addressing perinatal transmission through the use of immunoprophylaxis can help contain the spread of HBV. Pregnant mothers with chronic hepatitis B have unique challenges and require specialized management during and after pregnancy. This review will look at the screening of pregnant women for hepatitis B, passive and active immunoprophylaxis, mechanisms of perinatal viral transmission and therapeutic considerations in pregnancy including possible teratogenicity and efficacy of medication. Other issues such as the mode of transmission and breastfeeding will be covered.

Original languageEnglish
Pages (from-to)421-429
Number of pages9
JournalAsian Pacific Journal of Tropical Disease
Volume5
Issue number6
DOIs
Publication statusPublished - 01-01-2015
Externally publishedYes

Fingerprint

Virus Diseases
Hepatitis B virus
Pregnant Women
Newborn Infant
Chronic Hepatitis B
Hepatitis B e Antigens
Liver Neoplasms
Pregnancy
Antiviral Agents
Mothers
Acute Liver Failure
Third Pregnancy Trimester
Infection
Breast Feeding
Viral Load
Hepatitis B
Liver Cirrhosis
Placenta
Immunoglobulins
India

All Science Journal Classification (ASJC) codes

  • Microbiology (medical)
  • Infectious Diseases

Cite this

Salman, Khan ; Rashmi ; Priti, Singh ; Molly, Madan ; Kumar, Virmani Sunil ; Zeenat, Siddiqui. / Hepatitis B virus infection in pregnant women and transmission to newborns. In: Asian Pacific Journal of Tropical Disease. 2015 ; Vol. 5, No. 6. pp. 421-429.
@article{2b57deeee2814f5a8a2cfcd4223c8796,
title = "Hepatitis B virus infection in pregnant women and transmission to newborns",
abstract = "Chronic hepatitis B affects over 350 million people worldwide. India represents the second largest pool of chronic hepatitis B virus (HBV) infection in the world with an estimated 40 million infected people. Vertical transmission is known to be the leading cause of infection and perinatal infection is associated with a very high rate of chronicity (up to 90{\%}). Hepatitis B e antigen (HBeAg) positivity indicates that replicative form of HBV may play a role in immunotolerance in utero by crossing the placenta. Up to 40{\%} of chronically infected individuals will die prematurely from complications such as acute liver failure, cirrhosis and hepatocellular cancer. In case of HBeAg positivity and high viral load of mother, HBV immunoglobulin is preferably given along with HBV vaccination. Antiviral therapy is recommended for use in the third trimester of pregnancy to reduce the perinatal transmission of HBV, however, use of antiviral therapy should be individualized during pregnancy. Addressing perinatal transmission through the use of immunoprophylaxis can help contain the spread of HBV. Pregnant mothers with chronic hepatitis B have unique challenges and require specialized management during and after pregnancy. This review will look at the screening of pregnant women for hepatitis B, passive and active immunoprophylaxis, mechanisms of perinatal viral transmission and therapeutic considerations in pregnancy including possible teratogenicity and efficacy of medication. Other issues such as the mode of transmission and breastfeeding will be covered.",
author = "Khan Salman and Rashmi and Singh Priti and Madan Molly and Kumar, {Virmani Sunil} and Siddiqui Zeenat",
year = "2015",
month = "1",
day = "1",
doi = "10.1016/S2222-1808(15)60809-X",
language = "English",
volume = "5",
pages = "421--429",
journal = "Asian Pacific Journal of Tropical Disease",
issn = "2222-1808",
publisher = "Elsevier BV",
number = "6",

}

Hepatitis B virus infection in pregnant women and transmission to newborns. / Salman, Khan; Rashmi; Priti, Singh; Molly, Madan; Kumar, Virmani Sunil; Zeenat, Siddiqui.

In: Asian Pacific Journal of Tropical Disease, Vol. 5, No. 6, 01.01.2015, p. 421-429.

Research output: Contribution to journalReview article

TY - JOUR

T1 - Hepatitis B virus infection in pregnant women and transmission to newborns

AU - Salman, Khan

AU - Rashmi,

AU - Priti, Singh

AU - Molly, Madan

AU - Kumar, Virmani Sunil

AU - Zeenat, Siddiqui

PY - 2015/1/1

Y1 - 2015/1/1

N2 - Chronic hepatitis B affects over 350 million people worldwide. India represents the second largest pool of chronic hepatitis B virus (HBV) infection in the world with an estimated 40 million infected people. Vertical transmission is known to be the leading cause of infection and perinatal infection is associated with a very high rate of chronicity (up to 90%). Hepatitis B e antigen (HBeAg) positivity indicates that replicative form of HBV may play a role in immunotolerance in utero by crossing the placenta. Up to 40% of chronically infected individuals will die prematurely from complications such as acute liver failure, cirrhosis and hepatocellular cancer. In case of HBeAg positivity and high viral load of mother, HBV immunoglobulin is preferably given along with HBV vaccination. Antiviral therapy is recommended for use in the third trimester of pregnancy to reduce the perinatal transmission of HBV, however, use of antiviral therapy should be individualized during pregnancy. Addressing perinatal transmission through the use of immunoprophylaxis can help contain the spread of HBV. Pregnant mothers with chronic hepatitis B have unique challenges and require specialized management during and after pregnancy. This review will look at the screening of pregnant women for hepatitis B, passive and active immunoprophylaxis, mechanisms of perinatal viral transmission and therapeutic considerations in pregnancy including possible teratogenicity and efficacy of medication. Other issues such as the mode of transmission and breastfeeding will be covered.

AB - Chronic hepatitis B affects over 350 million people worldwide. India represents the second largest pool of chronic hepatitis B virus (HBV) infection in the world with an estimated 40 million infected people. Vertical transmission is known to be the leading cause of infection and perinatal infection is associated with a very high rate of chronicity (up to 90%). Hepatitis B e antigen (HBeAg) positivity indicates that replicative form of HBV may play a role in immunotolerance in utero by crossing the placenta. Up to 40% of chronically infected individuals will die prematurely from complications such as acute liver failure, cirrhosis and hepatocellular cancer. In case of HBeAg positivity and high viral load of mother, HBV immunoglobulin is preferably given along with HBV vaccination. Antiviral therapy is recommended for use in the third trimester of pregnancy to reduce the perinatal transmission of HBV, however, use of antiviral therapy should be individualized during pregnancy. Addressing perinatal transmission through the use of immunoprophylaxis can help contain the spread of HBV. Pregnant mothers with chronic hepatitis B have unique challenges and require specialized management during and after pregnancy. This review will look at the screening of pregnant women for hepatitis B, passive and active immunoprophylaxis, mechanisms of perinatal viral transmission and therapeutic considerations in pregnancy including possible teratogenicity and efficacy of medication. Other issues such as the mode of transmission and breastfeeding will be covered.

UR - http://www.scopus.com/inward/record.url?scp=84931824367&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84931824367&partnerID=8YFLogxK

U2 - 10.1016/S2222-1808(15)60809-X

DO - 10.1016/S2222-1808(15)60809-X

M3 - Review article

AN - SCOPUS:84931824367

VL - 5

SP - 421

EP - 429

JO - Asian Pacific Journal of Tropical Disease

JF - Asian Pacific Journal of Tropical Disease

SN - 2222-1808

IS - 6

ER -